EcoDrugPlus

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSFCAG00000009327
Gene Symbol: GART
5 Cross references
247 Possible Orthologues:

Plasminogen

Ensembl ID : ENSFCAG00000023975
Gene Symbol: PLG
5 Cross references
269 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSFCAG00000003517
Gene Symbol: PLAT
5 Cross references
203 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSFCAG00000012031
Gene Symbol: PTAFR
5 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSFCAG00000009141
Gene Symbol: PDGFRA
5 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSFCAG00000003634
Gene Symbol: PDGFRB
5 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSFCAG00000015580
Gene Symbol: PDGFB
5 Cross references
263 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSFCAG00000012944
Gene Symbol: PLK1
5 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSFCAG00000000135
Gene Symbol: PLK4
5 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSFCAG00000005777
Gene Symbol: PARP1
5 Cross references
207 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSFCAG00000006925
Gene Symbol: PARP2
5 Cross references
186 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSFCAG00000009146
Gene Symbol: PARP3
5 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).